EPIGENOMICS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.64 EUR | 0.00% |
|
+1.23% | -13.23% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 1.44M 1.55M |
|---|---|---|---|---|---|
| Net income 2024 * | - 0 | Net income 2025 * | - 0 | EV / Sales 2024 * | - |
| Net cash position 2024 * | 2.48M 2.67M | Net cash position 2025 * | 1.39M 1.49M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.84
x | P/E ratio 2025 * |
-2.87
x | Employees | 18 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 66.77% |
More Fundamentals
* Assessed data
More press releases
More news
| 1 week | +1.23% | ||
| Current month | +3.80% | ||
| 1 month | -5.48% | ||
| 3 months | -13.00% | ||
| 6 months | -33.06% | ||
| Current year | -13.23% |
1 week
1.60
1.64
1 month
1.551.72
Current year
1.551.90
1 year
1.556.20
3 years
1.5537.96
5 years
1.55512.00
10 years
1.551 191.20
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 1.64 | 0.00% | 1 571 |
| 24-05-09 | 1.64 | 0.00% | 23 |
| 24-05-08 | 1.64 | 0.00% | 75 |
| 24-05-07 | 1.64 | 0.00% | 75 |
| 24-05-06 | 1.64 | +1.23% | 75 |
Delayed Quote Xetra, May 10, 2024 at 11:36 am EDT
More quotes
Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
Calendar
2024-05-28
- Annual General Meeting
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.64
EUR
Average target price
15.8
EUR
Spread / Average Target
+863.41%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -13.23% | 1.56M | |
| -27.66% | 9.96B | |
| +35.36% | 3.76B | |
| -16.99% | 2.37B | |
| -11.15% | 2.27B | |
| -22.28% | 1.58B | |
| +59.62% | 1.31B | |
| -1.31% | 750M | |
| +23.25% | 575M | |
| -28.37% | 525M |
- Stock Market
- Equities
- ECX Stock
